Fotocitizen / Pixabay

Rare Community Profiles: From Stage 4 Cholangiocarcinoma to Cancer-Free in 12 Months: How Hepatic Artery Infusion (HAI) Changed Rick’s Trajectory

• Post author:Jessica Lynn
• Post published:February 8, 2024
• Post category:Bile duct cancer/Biliary tract cancer/Cholangiocarcinoma

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: From Stage 4 Cholangiocarcinoma to Cancer-Free in 12 Months: How Hepatic Artery Infusion (HAI) Changed Rick’s Trajectory

Source: pixabay.com

NXP800 for Cholangiocarcinoma Earns Orphan Drug Designation

• Post author:Jessica Lynn
• Post published:September 11, 2023
• Post category:Bile duct cancer/Biliary tract cancer/Cholangiocarcinoma

  In the United States, the FDA grants Orphan Drug designation to drugs or biologics that are intended to treat, diagnose, or prevent rare conditions. A rare condition is one…

Continue Reading NXP800 for Cholangiocarcinoma Earns Orphan Drug Designation

skeeze / Pixabay

Zanidatamab Could Treat HER2 Mutated Bile Duct Cancer

• Post author:Jessica Lynn
• Post published:June 21, 2023
• Post category:Bile duct cancer/Cholangiocarcinoma

Zanidatamab is an investigational IgG1 bi-specific monoclonal antibody that targets two non-overlapping HER2 domains. HER2 is overexpressed in a variety of cancer types such as breast cancer and esophageal cancer.…

Continue Reading Zanidatamab Could Treat HER2 Mutated Bile Duct Cancer

source: pixabay.com

A Glimmer of Hope for Patients with Advanced Biliary Tract Cancer

• Post author:Rose Duesterwald
• Post published:May 23, 2023
• Post category:Bile duct cancer/Biliary tract cancer/Cholangiocarcinoma

    For patients who were given a diagnosis of advanced, inoperable (unresectable) biliary tract cancer, an article appeared in Healio with some encouraging news. Gemcitabine and cisplatin drugs have…

Continue Reading A Glimmer of Hope for Patients with Advanced Biliary Tract Cancer

source: pixabay.com

ZB131 for Cholangiocarcinoma Earns Orphan Drug Designation

• Post author:Jessica Lynn
• Post published:December 19, 2022
• Post category:Bile duct cancer/Biliary tract cancer/Cholangiocarcinoma

  Rare diseases are, by their nature, rare—and because of this, it can be difficult to spur drug development. The FDA worked to overcome this through the creation of the…

Continue Reading ZB131 for Cholangiocarcinoma Earns Orphan Drug Designation

source: pixabay.com

Nelson is Running the Boston Marathon in Honor of His Brother, Who Died From Cholangiocarcinoma

• Post author:James Moore
• Post published:April 18, 2022
• Post category:Bile duct cancer/Biliary tract cancer/Cholangiocarcinoma

Nelson Ambrogio had always looked up to his older brother, Daniel. He has many positive memories of growing up with him. They both shared a passion for soccer, and Nelson…

Continue Reading Nelson is Running the Boston Marathon in Honor of His Brother, Who Died From Cholangiocarcinoma

source: pixabay.com

Phase 3 Global Trial for Cholangiocarcinoma Testing a Single Agent is Well Underway

• Post author:Trudy Horsting
• Post published:July 30, 2021
• Post category:Bile duct cancer/Cholangiocarcinoma

Updates from the Phase 3 clinical trial called FIGHT-302 were just released at the 2021 European Society for Medical Oncology World Congress on Gastrointestinal Cancer. The trial is comparing two…

Continue Reading Phase 3 Global Trial for Cholangiocarcinoma Testing a Single Agent is Well Underway

source: pixabay.com

Devimistat for Biliary Cancer Granted Orphan Drug Status

• Post author:Jessica Lynn
• Post published:July 9, 2021
• Post category:Bile duct cancer/Biliary tract cancer/Cholangiocarcinoma

  According to MPR, the FDA recently granted Orphan Drug designation to CPI-613 (devimistat), an investigational treatment designed for patients with biliary cancer. Altogether, "biliary cancer" can consist of bile…

Continue Reading Devimistat for Biliary Cancer Granted Orphan Drug Status

source: pixabay.com

The Second Ever FDA Approved Drug for Cholangiocarcinoma (CCA)

• Post author:Sunniva Bean
• Post published:July 6, 2021
• Post category:Bile duct cancer/Cholangiocarcinoma

As reported in Fierce Pharma; BridgeBio has earned FDA approval for their new targeted cancer treatment, Truseltiq. The approval is the biotech company’s first ever approval for a cancer drug,…

Continue Reading The Second Ever FDA Approved Drug for Cholangiocarcinoma (CCA)

source: pixabay.com

ICP-192 for Cholangiocarcinoma Granted Orphan Drug Status

• Post author:Jessica Lynn
• Post published:June 22, 2021
• Post category:Bile duct cancer

  As reported by Oncology Nursing News, gunagratinib (ICP-192) was recently granted Orphan Drug designation by the FDA. Altogether, this treatment is being evaluated as a potential treatment for patients…

Continue Reading ICP-192 for Cholangiocarcinoma Granted Orphan Drug Status

stevepb / Pixabay

Truseltiq Approved for Metastatic Cholangiocarcinoma

• Post author:Jessica Lynn
• Post published:June 21, 2021
• Post category:Bile duct cancer/Biliary tract cancer/Cholangiocarcinoma

In late May 2021, the FDA granted accelerated approval to Truseltiq (infigratinib). As reported by Cure, this therapy is designed for adult patients with unresectable locally advanced, previously treated, or…

Continue Reading Truseltiq Approved for Metastatic Cholangiocarcinoma

Study: Combination Therapy is an Effective Treatment for Cholangiosarcoma

• Post author:Kendall Mason
• Post published:August 20, 2020
• Post category:Bile duct cancer/Rare Disease

A study conducted at the University of Texas has discovered that combination therapy may be a viable treatment for cholangiocarcinoma with BRAF mutations. Researchers treated participants with both dabrafenib and…

Continue Reading Study: Combination Therapy is an Effective Treatment for Cholangiosarcoma

source: pixabay.com

Could This Investigational Drug be the Latest Advancement for Cholangiocarcinoma?

• Post author:James Moore
• Post published:February 12, 2020
• Post category:Bile duct cancer/Rare Disease

According to a story from curetoday.com, Dr. Tara Seery is an investigator in a phase 3 trial called PROOF, and she has just one goal: finding better treatments for cholangiocarcinoma,…

Continue Reading Could This Investigational Drug be the Latest Advancement for Cholangiocarcinoma?

source: pixabay.com

New Designations for Infigratinib, a Treatment for Cholangiocarcinoma

• Post author:Kendall Mason
• Post published:January 21, 2020
• Post category:Bile duct cancer/Rare Disease

  BridgeBio Pharmaceuticals has recently announced that their drug, infigratinib, has received the Fast Track and Orphan Drug designations from the FDA. This drug is meant for the treatment of…

Continue Reading New Designations for Infigratinib, a Treatment for Cholangiocarcinoma

A Blood Test That Can Detect Seven Types of Cancer

• Post author:Rose Duesterwald
• Post published:June 10, 2019
• Post category:Bile duct cancer/Ovarian Cancer/Pancreatic Cancer/Stomach Cancer

  Health News Digest recently published an article that describes a simple blood test called DELFI, meaning DNA evaluation of fragments for early interception. Its simplicity belies the fact that it can detect…

Continue Reading A Blood Test That Can Detect Seven Types of Cancer